我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
招募中
100.0%
暂无批准数据
- A large retrospective multicenter study of 2,405 eyes found no increased risk of glaucoma or ocular hypertension with high-volume intravitreal agents avacincaptad pegol, pegcetacoplan, and aflibercept 8mg compared to standard 50 µL injections. - The study analyzed treatment-naïve patients with neovascular age-related macular degeneration over 18-24 months, showing stable intraocular pressure across all treatment groups with differences within 1 mmHg. - These real-world findings corroborate clinical trial data and provide reassurance for clinicians using the three FDA-approved high-volume therapies that entered the market in 2023.
